SYRE Spyre Therapeutics Inc.
Price (delayed)
$18.03
Market cap
$1.09B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.18
Enterprise value
$997.35M
aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of
Highlights
The company's equity has surged by 181% YoY and by 58% QoQ
Spyre Therapeutics's quick ratio has surged by 55% QoQ and by 5% YoY
SYRE's EPS has shrunk by 115% QoQ but it has soared by 77% YoY
SYRE's revenue has shrunk by 100% YoY
The gross profit has dropped by 100% year-on-year
Key stats
What are the main financial stats of SYRE
Market
Valuations
Earnings
Shares outstanding
60.28M
Market cap
$1.09B
Enterprise value
$997.35M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.79
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$208.57M
Net income
-$208.02M
EBIT
-$207.97M
EBITDA
-$207.97M
Free cash flow
-$157.41M
Per share
Balance sheet
Liquidity
EPS
-$3.18
EPS diluted
-$3.18
Free cash flow per share
-$3.35
Book value per share
$10.07
Revenue per share
$0
TBVPS
$12.94
Total assets
$608.48M
Total liabilities
$90.68M
Debt
$0
Equity
$517.8M
Working capital
$554.41M
Debt to equity
0
Current ratio
11.26
Quick ratio
11.16
Net debt/EBITDA
0.43
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-42.6%
Return on equity
-60.7%
Return on invested capital
-62%
Return on capital employed
-37.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SYRE stock price
How has the Spyre Therapeutics stock price performed over time
Intraday
-4.5%
1 week
-12.05%
1 month
-20.5%
1 year
-59.49%
YTD
-22.55%
QTD
-22.55%
Financial performance
How have Spyre Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$208.57M
Net income
-$208.02M
Gross margin
N/A
Net margin
N/A
SYRE's revenue has shrunk by 100% YoY
The gross profit has dropped by 100% year-on-year
The net income has increased by 39% year-on-year and by 3.2% since the previous quarter
Spyre Therapeutics's operating income has increased by 14% YoY but it has decreased by 8% QoQ
Growth
What is Spyre Therapeutics's growth rate over time
Valuation
What is Spyre Therapeutics stock price valuation
P/E
N/A
P/B
1.79
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
SYRE's EPS has shrunk by 115% QoQ but it has soared by 77% YoY
The company's equity has surged by 181% YoY and by 58% QoQ
SYRE's P/B is 61% below its last 4 quarters average of 4.6 and 31% below its 5-year quarterly average of 2.6
SYRE's revenue has shrunk by 100% YoY
Efficiency
How efficient is Spyre Therapeutics business performance
Spyre Therapeutics's ROA has soared by 73% YoY and by 16% from the previous quarter
SYRE's return on invested capital is up by 28% since the previous quarter
The company's return on equity rose by 27% QoQ
Dividends
What is SYRE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SYRE.
Financial health
How did Spyre Therapeutics financials performed over time
Spyre Therapeutics's total assets has surged by 78% YoY and by 45% QoQ
Spyre Therapeutics's quick ratio has surged by 55% QoQ and by 5% YoY
Spyre Therapeutics's debt is 100% lower than its equity
The company's equity has surged by 181% YoY and by 58% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.